AI assistant
Whitbread PLC — Regulatory Filings 2018
Nov 29, 2018
4608_rns_2018-11-29_dfeed4da-e2fa-465d-b227-fe73fda787ce.html
Regulatory Filings
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 9344I
Whitbread PLC
29 November 2018
Sale of Costa to Coca-Cola receives approval from China regulator
Whitbread PLC is pleased to announce that clearance has been received from China's State Administration for Market Regulation for The Coca-Cola Company to acquire Costa Limited, including its operations in China.
Clearance is still required from the European Union under the EC Merger Regulation before the transaction can complete and certain completion deliverables remain outstanding including an agreement still to be reached with the Trustees of the pension fund.
This announcement contains inside information.
For more information please contact:
Investor queries
Matt Johnson, Whitbread PLC | [email protected] | +44 (0) 7848 146 761
Ann Hyams, Whitbread PLC | [email protected] | +44 (0) 7796 709 087
Media queries
Anna Glover, Whitbread PLC | +44 (0) 7768 917 651
David Allchurch / Jessica Reid, Tulchan Communications | +44 (0) 20 7353 4200
For photographs and video please visit Whitbread's media library at www.whitbread.co.uk/media.
Goldman Sachs International ("Goldman Sachs") and Morgan Stanley & Co. International plc ("Morgan Stanley") are acting as joint financial advisers and joint sponsors to Whitbread. Deutsche Bank AG, acting through its London branch ("Deutsche Bank") is acting as financial adviser to Whitbread. Morgan Stanley and Deutsche Bank are acting as corporate brokers to Whitbread. Slaughter and May is acting as legal adviser to Whitbread.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DISLKLFLVFFLFBD